Roquette has announced the successful completion of its acquisition of IFF Pharma Solutions, marking a strategic milestone in its ambition to become a leading supplier of pharmaceutical excipients and drug delivery solutions globally.

The deal builds on Roquette’s 2023 acquisition of Qualicaps and significantly broadens its technical portfolio and geographic reach. By integrating IFF’s polymer science and formulation technologies, Roquette aims to provide a more comprehensive offering to pharmaceutical customers developing both traditional and complex therapies.

“This pivotal move aligns perfectly with our strategic vision to provide innovative, high-quality excipients that improve the efficacy and safety of pharmaceutical formulations,” said Roquette CEO Pierre Courduroux.

“By combining our strengths, Roquette is poised to become the pharmaceutical industry’s go-to partner for advanced drug delivery solutions.”

The acquisition underscores a broader trend in the excipients sector, where suppliers are scaling up capabilities to support increasingly sophisticated drug delivery platforms, including those used in mRNA vaccines, targeted oncology treatments, and long-acting injectables. As the pharmaceutical industry evolves beyond small molecules toward more complex biologics and patient-centric dosage forms, excipient suppliers are being asked to deliver greater technical expertise and regulatory support.

IFF Pharma Solutions brings formulation know-how and a global footprint, including manufacturing sites in North America and Asia-Pacific, which could help Roquette serve a wider range of customers across regional markets. Analysts note that the consolidation of formulation expertise and global manufacturing capacity may also help both companies respond to growing pressure for supply chain resilience and GMP compliance.

Financial terms of the deal were not disclosed. The companies will now begin integration efforts, with a focus on aligning product pipelines and harmonizing quality systems.